-+ 0.00%
-+ 0.00%
-+ 0.00%

Morgan Stanley Maintains Overweight on Nurix Therapeutics, Raises Price Target to $38

Benzinga·07/28/2026 17:00:41
語音播報
Morgan Stanley analyst Terence Flynn maintains Nurix Therapeutics (NASDAQ:NRIX) with a Overweight and raises the price target from $36 to $38.